geographic atrophy

News

Complement raises €72m for geographic atrophy gene therapy

UK start-up Complement Therapeutics has raised an impressive €72 million ($79 million) in first-round financing that will be used to take a gene therapy for sight-robbing

News

Apellis breaks new ground in geographic atrophy

Syfovre is the first FDA-approved drug for GA, which damages the sight of 5m people worldwide.

Views & Analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

News

Longer-term data raise prospects for Apellis' pegcetacoplan

Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Novartis adds gene therapy for blindness with Gyroscope buy

Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect.

News

Sanofi winds $40m into UK gene therapy firm Gyroscope

French drugmaker Sanofi has made a $40 million investment in Gyroscope Therapeutics, with another $20 million potentially on offer as the UK biotech advances its clinical-stage gene therapi

Complement raises €72m for geographic atrophy gene therapy

Apellis breaks new ground in geographic atrophy

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Longer-term data raise prospects for Apellis' pegcetacoplan

Novartis adds gene therapy for blindness with Gyroscope buy

Sanofi winds $40m into UK gene therapy firm Gyroscope

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

geographic atrophy

Editor's Picks